NCT03239145 2026-03-12
Pembrolizumab (Anti-PD-1) and AMG386 (Angiopoietin-2 (Ang-2) in Patients With Advanced Solid Tumor
Dana-Farber Cancer Institute
Phase 1 Completed
Clinical Trials
35 trialsNCT03519412 2026-03-03
ARETHUSA
IFOM ETS - The AIRC Institute of Molecular Oncology
Phase 2 Completed
NCT07410676 2026-02-18
EBNK-ST-001
Essen Biotech
Phase 1/2 Recruiting
NCT02600949 2026-01-29
Personalized Peptide Vaccine in Treating Patients With Advanced Pancreatic Cancer or Colorectal Cancer
M.D. Anderson Cancer Center
Phase 1 Active not recruiting
NCT03844750 2025-12-31
Preoperative Immunotherapy (Pembrolizumab) for Patients With Colorectal Cancer and Resectable Hepatic Metastases
University of California, San Francisco
Phase 2 Terminated
NCT04729322 2025-12-23
Fecal Microbiota Transplant and Re-introduction of Anti-PD-1 Therapy (Pembrolizumab or Nivolumab) for the Treatment of Metastatic Colorectal Cancer in Anti-PD-1 Non-responders
M.D. Anderson Cancer Center
Phase 2 Active not recruiting
NCT04157985 2025-12-11
Evaluating Length of Treatment With PD-1/PD-L1 Inhibitor in Advanced Solid Tumors
University of Pittsburgh
Phase 3 Completed
NCT05131919 2025-12-09
PUMA
The Netherlands Cancer Institute
Phase 2 Active not recruiting
NCT03984578 2025-11-18
Window of Opportunity Study in Colorectal Cancer
National Cancer Centre, Singapore
Phase 2 Completed
NCT06846268 2025-07-25
Neoadjuvant ADG126 and Pembrolizumab in Locally Advanced Colorectal Cancer
National University Hospital, Singapore
Phase 2 Recruiting
NCT03657641 2025-07-04
Regorafenib and Pembrolizumab in Treating Participants With Advanced or Metastatic Colorectal Cancer
University of Southern California
Phase 1/2 Active not recruiting
NCT03396926 2025-02-28
Pembrolizumab, Capecitabine, and Bevacizumab for Treating Colorectal Cancer
University of California, San Francisco
Phase 2 Completed
NCT05167409 2025-01-13
A Study of Evorpacept (ALX148) With Cetuximab and Pembrolizumab for Refractory Microsatellite Stable Metastatic Colorectal Cancer
University of Colorado, Denver
Phase 2 Active not recruiting
NCT06530303 2024-11-05
BAH248
Essen Biotech
Phase 1/2 Recruiting
NCT05518032 2024-09-26
Pembrolizumab and Autologous Dendritic Cells for the Treatment of Refractory Colorectal Cancer (CRC)
Roswell Park Cancer Institute
Phase 2 Withdrawn
NCT03475004 2024-09-19
Study of Pembrolizumab, Binimetinib, and Bevacizumab in Patients With Refractory Colorectal Cancer
University of Colorado, Denver
Phase 2 Completed
NCT05609656 2024-06-03
ELI
Zealand University Hospital
Phase 2 Terminated
NCT05746897 2024-01-26
A First-in-human, Phase I, Open-label, Multicenter Study of NM1F(Anti-PVRIG) in Patients With Advanced Solid Tumors
Hefei TG ImmunoPharma Co., Ltd.
Phase 1 Recruiting
NCT03095781 2023-12-05
Pembrolizumab and XL888 in Patients With Advanced Gastrointestinal Cancer
Emory University
Phase 1 Completed
NCT05909423 2023-06-18
FLU-IMMUNE
Zealand University Hospital
Phase 2 Not yet recruiting
NCT05201612 2023-02-24
PEMBROLA
Grupo Espanol Multidisciplinario del Cancer Digestivo
Phase 2 Unknown
NCT05725200 2023-02-21
EVIDENT
Oslo University Hospital
Phase 2 Recruiting
NCT04014530 2023-02-01
ATAPEMBRO
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Phase 1/2 Recruiting
NCT02713373 2022-10-06
Cetuximab and Pembrolizumab in Treating Patients With Colorectal Cancer That is Metastatic or Cannot Be Removed by Surgery
Roswell Park Cancer Institute
Phase 1/2 Completed
NCT03274804 2022-06-07
PICCASSO
University Hospital Heidelberg
Phase 1 Completed
NCT03332498 2022-06-03
Pembrolizumab in Combination With Ibrutinib for Advanced, Refractory Colorectal Cancers
H. Lee Moffitt Cancer Center and Research Institute
Phase 1/2 Completed
NCT05333809 2022-04-20
Pembrolizumab and Disitamab Vedotin in HER2-expressing Metastatic Colorectal Cancer
Shanghai Zhongshan Hospital
Phase 2 Unknown
NCT02375672 2022-02-16
Study of Pembrolizumab in Combination With Chemotherapy for Patients With Advanced Colorectal Cancer
Hoosier Cancer Research Network
Phase 2 Completed
NCT04119830 2022-02-08
Rintatolimod and Pembrolizumab for the Treatment of Refractory Metastatic or Unresectable Colorectal Cancer
Roswell Park Cancer Institute
Phase 2 Withdrawn
NCT02851004 2021-09-05
Special Combination of BBI608 and Pembrolizumab
National Cancer Center Hospital East
Phase 1/2 Terminated
NCT02981524 2021-02-10
Study of GVAX (With CY) and Pembrolizumab in MMR-p Advanced Colorectal Cancer
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 2 Completed
NCT02757391 2020-10-30
CD8+ T Cell Therapy and Pembrolizumab in Treating Patients With Metastatic Gastrointestinal Tumors
M.D. Anderson Cancer Center
Phase 1 Terminated
NCT02318901 2019-10-21
PembroMab
Western Regional Medical Center
Phase 1/2 Terminated
NCT02260440 2019-09-17
A Phase 2 Study of Pembrolizumab (MK-3475) in Combination With Azacitidine in Subjects With Chemo-refractory Metastatic Colorectal Cancer
University of Pittsburgh
Phase 2 Completed
NCT03182894 2018-08-28
Epacadostat in Combination With Pembrolizumab and Azacitidine in Subjects With Metastatic Colorectal Cancer
University of Pittsburgh
Phase 1/2 Withdrawn